ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,701Medicare Part D Prescriptions Filled, Including Refills

Rank: 27 out of 97

$380K Total Retail Price of All Prescriptions

Rank: 35 out of 97

428 Patients Receiving at Least One Drug in Part D
95%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Dakota
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 428 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 428 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 9,295 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$39 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Dakota
SIMVASTATIN 550 541 1 2
LEVOTHYROXINE SODIUM 484 468 2 1
LISINOPRIL 482 460 3 4
METOPROLOL SUCCINATE 444 442 4 8
HYDROCODONE-ACETAMINOPHEN 410 370 S3 5 17
FUROSEMIDE 378 378 6 3
OMEPRAZOLE 299 280 7 5
AMLODIPINE BESYLATE 292 284 8 6
HYDROCHLOROTHIAZIDE 262 249 9 9
SERTRALINE HCL 248 239 10 16
ATORVASTATIN CALCIUM 233 232 11 14
METOPROLOL TARTRATE 219 219 12 7
METFORMIN HCL 209 195 13 12
JANTOVEN 201 177 14 37
LOSARTAN POTASSIUM 174 174 15 13
ATENOLOL 171 171 16 15
TRAMADOL HCL 159 146 17 21
POTASSIUM CHLORIDE 157 157 18 10
WARFARIN SODIUM 120 120 19 11
DIGOXIN 109 109 20 26
AZITHROMYCIN 106 101 21 64
GLIMEPIRIDE 97 93 22 39
ISOSORBIDE MONONITRATE ER 95 95 23 27
CRESTOR 95 95 23 29
PRAVASTATIN SODIUM 91 91 25 28
CLOPIDOGREL 89 89 26 34
ALENDRONATE SODIUM 80 80 27 19
MORPHINE SULFATE ER 80 80 S2 27 137
LOSARTAN-HYDROCHLOROTHIAZIDE 77 77 29 49
ZOLPIDEM TARTRATE 77 68 29 32
PAROXETINE HCL 72 72 31 56
LANTUS 70 63 32 43
CARVEDILOL 69 61 33 25
ZETIA 68 68 34 51
ALLOPURINOL 64 63 35 22
LISINOPRIL-HYDROCHLOROTHIAZIDE 62 56 36 36
ADVAIR DISKUS 60 48 37 40
DILTIAZEM 24HR CD 60 60 37 73
PREDNISONE 59 57 39 23
GABAPENTIN 57 47 40 18
PLAVIX 52 52 41 46
DOXAZOSIN MESYLATE 52 41 41 45
MIRTAZAPINE 51 51 43 35
TAMSULOSIN HCL 50 42 44 31
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 20, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.